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The scope of cancer treatment inwomenof childbearing age has changed in the last decade.
Fertility preservation is no longer an afterthought but central to multi-disciplinary cancer
treatment planning and should be addressed due to the cytotoxic effects of cancer ther-
apy. However, oncology patients present as a unique treatment challenge as the physician
must balance the urgency of fertility preservation with the risks of delaying cancer therapy.
Controlled ovarian stimulation (COS) is routinely applied in assisted reproductive technol-
ogy but can be contraindicated in women with estrogen-receptor-positive tumors. This
paper reviews some of the challenges to consider when using COS and newer stimulation
protocols to minimize risks and optimize outcomes in oncofertility patients.
Keywords: oncofertility, controlled ovarian stimulation, assisted reproduction, follicular phase, luteal phase
INTRODUCTION
Fertility preservation for female cancer patients prior to cancer
therapy has emerged as an essential component of comprehensive
patient care. In a survey questioning, the importance of fertil-
ity preservation in women of childbearing age recently diagnosed
with cancer, 77.6% (66 of 85) reported that the possibility of pre-
serving their fertility was instrumental to coping before and after
treatment (1).
In the U.S., approximately 6% of women diagnosed with inva-
sive cancer between 2007 and 2011 were <45 years old (2). The
incidence of cancers in reproductive age women signifies a need
for fertility preservation options, and this need is increasing with
the current trend of delayed childbearing and increased cancer
survival. The birth rate for women aged 35–44 rose 54% from
1990 to 2011, increasing the number of women diagnosed with
cancer who may wish to conceive after cancer treatment (3).
Additionally, there has been a significant increase in cancer sur-
vival rates during the past decade due to earlier diagnoses and
improved cancer treatments (4). From 2002 to 2012, 83% of
female patients <45 years old diagnosed with cancer survived
>5 years (5).
Cancer treatment is cytotoxic and may result in complete or
partial ovarian failure with subsequent subfertility, sterility, and
premature menopause. All chemotherapies have the potential to
damage developing follicles; this can result in temporary amenor-
rhea. If the primordial follicle pool is not permanently damaged,
menses will return, with the development of new follicles within
3–6 months after the last treatment (6). Studies indicate that alky-
lating agents are particularly gonadotoxic (7), with significantly
diminished ovarian response demonstrated in those who received
alkylating agents prior to oocyte retrieval (8). Pelvic radiation
therapy is also highly gonadotoxic to oocytes, causing follicular
destruction, resulting in premature ovarian insufficiency in many
women (9). Similar to chemotherapy, this follicular depletion and
ovarian decline from treatment accelerates the onset of menopause
(10). The resulting damage is dose-related and depends on ovar-
ian reserve and age at time of treatment (11). Young women are
presumed to be less affected by gonadotoxic agents due to a larger
reserve of primordial follicles, but it is established that they are at
risk of accelerated follicular loss, premature ovarian failure, and
infertility (12).
Effects of cancer may also include an increased catabolic state,
stress, and malnutrition, resulting in an adverse effect on all organ
systems. Furthermore, enhanced stress hormones and hypothala-
mic dysfunction lead to decreased levels of gonadotropins, which
in turn impacts fertility (13). These factors may lead to dimin-
ished ovarian reserve, yielding lower oocyte recovery at oocyte
retrieval (14). For breast cancer patients, oocytes may be at risk
for DNA damage, resulting from BRCA gene mutations (15). A
meta-analysis demonstrated a statistical significance when com-
paring the number of retrieved oocytes for those in the cancer
group compared to controls: 11.7± 7.5 vs. 13.5± 8.4, p= 0.002
(95% CI,−2.976; −0.621) (14). Retrievals and cancelations were
significantly lower and higher, respectively, in cancer patients com-
pared to healthy age-matched individuals (14). Thus, the ovarian
reserve and oocyte quality of cancer patients prior to undergoing
fertility preservation may already be poorer than that of a healthy
individual.
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Multiple strategies are available to preserve fertility in these
patients, including embryo and oocyte cryopreservation, corti-
cal and whole ovary cryopreservation, ovarian transplantation,
ovarian transposition, in vitro maturation of immature oocytes,
and ovarian suppression with gonadotropin-releasing hormone
(GnRH) analogs (16). There have been several recent advance-
ments in assisted reproductive technology (ART) that provide
potential new options for fertility preservation in this patient
population. Currently, embryo and mature oocyte cryopreser-
vation following in vitro fertilization (IVF) are the only tech-
niques endorsed by the American Society for Reproductive Med-
icine (ASRM) as standard therapies; all other methods are still
considered investigational (17, 18).
Controlled ovarian stimulation (COS) for oocyte/embryo cry-
opreservation is still the preferred method for fertility preservation
due to its higher success compared to other technologies. Special
considerations must be taken into account for a cancer patient
undergoing fertility preservation using COS, including the opti-
mal dosing, timing strategies, and the risks of increased estrogen
exposure and delay in treatment with those who develop ovarian
hyperstimulation syndrome (OHSS). This paper will review the
current knowledge of fertility preservation options and the clin-
ical challenges and strategies to optimize treatment outcomes in
cancer patients undergoing fertility preservation.
CHALLENGES AND CONSIDERATIONS
TIME CONSTRAINTS AND AVOIDING RISKS
Preserving a woman’s fertility requires time for ovarian stimu-
lation and oocyte retrieval. Traditionally, COS is initiated at the
start of the follicular phase with the premise that it is the optimal
time for recruitment of the ovarian follicular pool, maximizing
the number of retrieved oocytes. This is particularly important
as there may be time for only one cycle of COS prior to initiat-
ing cancer therapy. However, waiting for the patient’s menstrual
cycle may require several weeks until one can undergo COS, which
would delay life-saving cancer therapy.
Ovarian hyperstimulation syndrome, an iatrogenic sequelae of
COS, is the most serious complication of ovarian stimulation,
occurring in 3–8% of IVF cycles (19), and cancer patients risk
a delay in therapy if OHSS develops (20). OHSS, in its sever-
est form, is associated with intravascular depletion, ascites, liver
dysfunction, pulmonary edema, electrolyte imbalance, and throm-
boembolic events. It is usually self-limited with spontaneous reso-
lution in a few days, but may progress in severity, rarely requiring
hospitalization.
Thromboembolic events are one of the most concerning events
as patients with a neoplasm inherently have a hypercoagulable
state that poses an increased risk of morbidity and mortality (21).
Cancer patients may therefore be at even greater risk if OHSS
develops following COS. Thus, identifying the optimal COS strat-
egy to maximize oocyte recruitment while preventing OHSS is
most ideal to avoid this serious complication.
CONCERNS WITH ESTROGEN-SENSITIVE CANCERS
Elevated serum estradiol (E2) levels as a result of COS with gona-
dotropins may promote growth of tumors in estrogen-sensitive
cancers, such as endometrial and estrogen-receptor-positive breast
cancers (22). The rise in E2 levels is directly proportional to the
number of recruited follicles, thus, protocols for these patients
must aim to reduce estrogen production (23).
PREPUBESCENT AND ADOLESCENT PATIENTS
Fertility preservation in pediatric and adolescent oncology patients
encompasses the full range of standard and experimental options.
In the prepubescent patient, ovarian tissue cryopreservation is
the only option and is still investigational. In the adolescent
patient, egg and embryo freezing are standard options similar
to reproductive age women while ovarian tissue freezing remains
investigational.
Some of the challenges include the process of patient assent and
parental consent and a thorough understanding of the process of
daily injections, serial ultrasounds, and lab testing with the chal-
lenges of cost, time, discomfort, and posthumous related issues.
These challenges can be mitigated by a comprehensive and realis-
tic discussion of the process using a team approach of empathic
nurses, social workers, and a financial team. Embryo freezing may
not be a feasible option in the adolescent patient who may not
be able to consent to use of partner or donor sperm. If time is
limited, ovarian tissue cryopreservation is an option. It involves
an oophorectomy typically with a minimally invasive approach
often combined with central line or port placement for chemother-
apy, thereby minimizing anesthetic risk and cost. As ovarian tissue
freezing remains experimental with 24 babies reported, to date
(24), establishing ovarian stimulation protocols for egg freezing
that maximize outcome and minimize discomfort in the adoles-
cent patient are necessary. In vitro maturation of immature oocytes
is a promising investigational technique that would negate the time
required for ovarian stimulation and would be an option for both
pre- and post-pubescent patients (25).
ASSESSMENT TO OPTIMIZE COS
The efficacy of oocyte retrieval and ovarian stimulation is directly
related to the quantity and quality of the patient’s current ovar-
ian reserve. Therefore, assessing reserve is important in counsel-
ing the patient adequately and to utilize protocols to optimize
oocyte yield while minimizing development of OHSS. Ovarian
reserve tests include basal follicle-stimulating hormone (FSH),
inhibin B, antral follicle count (AFC), ovarian volume assessed
by transvaginal ultrasound, and anti-Mullerian hormone (AMH).
Unlike basal cycle day 2–3 FSH and estradiol, serum levels of
AMH, which can be performed at any time of the menstrual
cycle, and AFC serve as good predictors of ovarian reserve and
response to COS. With respect to those with cancer, there are
mixed reports on the predictive value of AMH (26) and AFC (27)
compared to patients without a cancer diagnosis. Responses to
COS are significantly lower in cancer patients with lower AMH
and AFC prior to undergoing chemotherapy with the require-
ment of higher doses of gonadotropins compared to healthy
age-matched women (28). It is therefore likely that the response
to COS is related to both the patient’s current ovarian reserve
and overall clinical condition (29). In addition, AMH neither pre-
dict spontaneous conception nor pregnancy or live birth after IVF
(30). As such, these factors are not definitive in predicting out-
comes but are useful for counseling patients, helping to develop
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FIGURE 1 | Options for COS for ART cycles. Conventional-start
begins in the luteal phase with or without administration of oral
contraceptive pills (OCPs) or GnRH-antagonists (GnRH-ant), and
proceeds after withdrawal bleeding with gonadotropins and
GnRH-ant, until hCG or GnRH-a trigger, and lastly transvaginal
aspiration (TVA) of oocytes. Random-start protocols may begin either
in late follicular or luteal phases, and may utilize spontaneous LH
surge or GnRH-a.
realistic expectations, and determining a safe and effective ovarian
stimulation protocol for the cancer patient undergoing fertility
preservation (31).
CURRENT AND POTENTIAL OVARIAN STIMULATION
PROTOCOLS
CONVENTIONAL CONTROLLED OVARIAN STIMULATION PROTOCOLS
Conventional-start COS is currently the preferred and established
method of ovarian stimulation for cancer patients (29). This pro-
tocol is initiated at the beginning of the follicular phase, and
requires 9–14 days of ovarian stimulation with gonadotropins fol-
lowed by 14 days of ovarian suppression with a GnRH agonist
(GnRH-a) during the luteal phase to prevent premature ovulation
(Figure 1). Thus, depending on a woman’s cycle at time of diagno-
sis, conventional-start COS may require 4–6 weeks, which could
represent a significant delay in commencing cancer therapy. COS
and IVF would not be a viable option for patients with rapidly
progressing neoplasms that require immediate therapy.
The development of newer generation GnRH-antagonists
(GnRH-ant) have successfully prevented a premature luteinizing
hormone (LH) surge during ovarian hyperstimulation for IVF
cycles. This is more optimal than conventional GnRH-a, allowing
the shortest delay of cancer therapy as it decreases the time between
diagnosis and oocyte or embryo cryopreservation (32). In com-
parison to traditional GnRH-a, GnRH-ant has the advantage of
immediate suppression of pituitary gonadotropins, preventing an
FSH and LH flare. This obviates the prolonged period to pituitary
suppression and has been reported to result in shorter treatment
cycles and less gonadotropin requirements (33).
For cancer patients waiting for their menses, GnRH-ant have
been administered during the preceding mid-luteal phase with
menses occurring a few days later (34). An alternate strategy is to
use oral contraceptive pills (OCPs) as pretreatment to regulate and
control withdrawal bleeding (35). OCPs avoid the need to wait for
natural onset of menses and deter selection of a lead follicle. They
are only an option in non-estrogen-sensitive cancers.
RANDOM-START CONTROLLED OVARIAN STIMULATION PROTOCOLS
Random-start COS protocols are emerging as an attractive
approach as they minimize delays in cancer therapy (29, 36–38).
Two different approaches, late follicular and luteal phase, have been
suggested for random-start COS protocols (Figure 1).
Late follicular phase
Late follicular phase protocols begin after menstrual cycle day
7 with emergence of a dominant follicle (>13 mm) (36). If the
follicle cohort following the lead follicle is<12 mm before a spon-
taneous LH surge, a protocol utilizing ovarian stimulation without
a GnRH-ant may be employed (36). After the LH surge, a GnRH-
ant is started later in the cycle when the secondary follicle cohort is
12 mm to prevent a premature secondary LH surge. If the follicle
cohort following the lead follicle is>12 mm before a spontaneous
LH surge, a protocol with a GnRH-ant for pituitary suppression
may be initiated (36). This GnRH-ant is continued until final
oocyte maturation with an hCG or GnRH-a trigger.
Luteal phase
Luteal phase protocols initiate ovarian stimulation in the absence
of GnRH-ant. If the oncology patient presents in the luteal phase
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or ovulation was induced with hCG or GnRH-a, ovarian stimula-
tion starts within 2–3 days in the early luteal phase (36). Similar to
conventional-start COS-GnRH-ant protocols, these luteal phase
start protocols utilize a GnRH-ant administered later in the cycle
to prevent a premature LH surge, and continue until the hCG or
GnRH-a triggers final oocyte maturation.
A study comparing stimulation in oncology patients with fol-
licular to luteal phase starts showed similar average numbers of
aspirated oocytes (13.1 vs. 10.0%) and fertilization rates (61.0
vs. 75.6%) (38). When comparing conventional-start COS and
random-start COS, Cakmak et al. demonstrated that the num-
bers of total metaphase-II oocytes retrieved and fertilization
rates were similar in oncology patients (36). While random-start
COS resulted in longer length of ovarian stimulation by ~2 days
(p< 0.001) and required higher average gonadotropin use (4,158
vs. 3,404 IU/day, p= 0.002), there was a significant advantage to
random-start COS with respect to time to treatment for cancer
(36). This is consistent with a novel concept that follicular recruit-
ment occurs in multiple waves during each menstrual cycle (39).
COS IN PATIENTS WITH ESTROGEN-SENSITIVE CANCER
Natural-cycle IVF without ovarian stimulation would be safe but
only produces one or two oocytes per cycle, has a high-cycle can-
celation rate, and thus, is not an optimal treatment choice even if
there is little time before onset of cancer therapy (29). There are
several alternative and safer protocols for estrogen-sensitive can-
cer patients that have been developed, though the efficacy of these
various protocols has yet to be well established.
For patients with estrogen-sensitive cancers, protocols have
been designed that include competitive inhibitors of estrogen
receptors or aromatase inhibitors (AIs) to reduce estrogen’s effect
or production, respectively. Tamoxifen is an estrogen agonist-
antagonist with agonist effects at the uterus and bone and antag-
onist effects in the breast and central nervous system (CNS).
Specifically, tamoxifen inhibits growth of breast tumors through
its anti-estrogenic action and is used as first-line treatment and
hormonal prevention in estrogen-sensitive cancers (40). In the
CNS, it interferes with the negative feedback of estrogen on the
hypothalamic-pituitary axis. This leads to increased GnRH secre-
tion from the hypothalamus, FSH release from the pituitary, and
stimulation of follicular development. In the uterus, tamoxifen
has been found to cause hyperplasia and increase the risk of uter-
ine cancer; therefore, it would not be recommended over AI for
augmenting COS.
Tamoxifen can be used for COS alone on cycle days 2
through 5 of the patient’s menstrual cycle or in combination
with gonadotropins (23). Ovarian stimulation with tamoxifen
alone in cancer patients increases the mature oocyte and embryo
yield compared with natural-cycle IVF and reduces cycle can-
celations (41). With a combined treatment of tamoxifen and
gonadotropins, this results in an even greater number of cryopre-
served oocytes/embryos (42). This is especially important due to
the fact that hormone-dependent cancers have been shown to have
a weaker response to COS compared to non-hormone-dependent
cancers (43).
Aromatase inhibitors, such as letrozole, reduce estrogen pro-
duction. Aromatase catalyzes the conversion of androstenedione to
estrone and of testosterone to E2 (44). AIs suppress plasma estro-
gen levels by competitively inhibiting the activity of aromatase
(45), with the goal of keeping E2 levels close to those observed
in natural cycles (46). In the CNS, AIs work similarly to estro-
gen inhibitors by blocking the negative feedback of estrogen on
the hypothalamic-pituitary axis, resulting in FSH release from the
pituitary and increased follicular growth (47). Letrozole is thus
effective at preventing estrogen production and can also be used
for ovulation induction.
Protocols with daily letrozole along with gonadotropins are pre-
ferred over tamoxifen because letrozole results in greater retrieved
and fertilized oocytes (42). Short-term follow-up of breast cancer
patients who had undergone ovarian stimulation with letrozole
and gonadotropins has not revealed any increased risk of breast
cancer recurrence (48). COS with AIs has also been safely used in
endometrial cancer patients (49). As such, AIs are recommended
as part of a safe, well tolerated, and effective protocol for fertility
preservation.
MINIMIZING RISK OF OHSS
During COS, it has been established that triggering final oocyte
maturation with hCG may induce OHSS. Recent data suggest that
GnRH-agonists (Leuprolide 0.5–1.0 mg SC) used to stimulate an
endogenous LH surge for oocyte maturation results in reduced risk
of OHSS due to the short half-life of the endogenously induced
LH surge and lower estrogen production, which is believed in
part to be the trigger for OHSS (50). When comparing the two,
GnRH-a reduce the risk of OHSS in autologous IVF cycles. In
fertility preservation cases, women with breast cancer also had
significantly reduced risk of OHSS (2.1 vs. 14.4%, p= 0.032) by
using GnRH-a triggers vs. hCG (51). However, this approach is
only useful in cycles not involving previous down-regulation with
GnRH-a, but may prove advantageous for patients with estrogen-
sensitive cancers by decreasing the progression of their cancer.
Future investigation is needed in this area due to limited studies
determining cancer progression after GnRH-a triggering (52).
One potential concern with GnRH-a is that trigger failures may
occur due to incomplete binding at GnRH receptors due to com-
petition with GnRH-ant leading to a limited LH surge (53). Thus,
in GnRH-ant fertility preservation protocols, a GnRH-a trigger
is only recommended for those who are at risk for OHSS (29),
and should be considered in the cancer patient who is to undergo
chemo-radiation therapy upon completion of COS (52).
Withholding gonadotropin stimulation and delaying hCG
administration until E2 levels plateau or decreases can reduce
the risks of OHSS. In autologous IVF cycles, evidence suggests
that “coasting” does not adversely affect outcomes in IVF cycles
unless it is prolonged>3 days (54, 55). To date, no reports on this
approach in fertility preservation and risks of OHSS have been
reported (56).
POSSIBLE PROPHYLACTIC CO-TREATMENT
Oncology patients are at increased risk of thromboembolic events
during COS because of their hypercoaguable state due to malig-
nancy and supraphysiologic serum E2 levels due to stimulation
(57). Anticoagulants, such as low-molecular-weight heparin, can
be administered to prevent coagulation, and letrozole may be used
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to maintain low serum E2 levels in order to prevent this risk (29).
In patients with bone marrow malignancies or liver involvement, it
is important to be vigilant about excessive bleeding and recognize
that platelet or fresh frozen plasma transfusion prior to oocyte
retrieval may be required (29). Neutropenic patients are at risk
of pelvic infection after retrieval; therefore, it may be appropriate
to consult the oncologist with recommendations for antibiotics
and/or granulocyte colony-stimulating factor to prevent infection.
In addition, ovarian suppression with GnRH-a during adju-
vant chemotherapy may be an option for patients without time
or resources available for other methods of fertility preservation
(58). Currently, studies involving GnRH-a for prevention of ovar-
ian failure after cytotoxic treatment are conflicting. However, this
treatment is often used for menstrual suppression in oncology
patients and thus a secondary benefit may be achieved with little
risk of harm.
CONCLUSION
Ovarian stimulation protocols must be individualized based on
time available prior to cancer treatment and fertility status of the
patient. Fertility preservation for oncology patients should be car-
ried out with a multi-disciplinary approach, including oncologists
and fertility specialists (59). Patients should meet with a reproduc-
tive endocrinologist as soon as possible after diagnosis of cancer
in order to begin consultation and treatment (60).
The main goal of fertility preservation treatment for
female cancer patients should be to maximize the number of
oocytes/embryos preserved while avoiding OHSS and delayed can-
cer therapy. Conventional-start COS is an established method
in fertility preservation and random-start COS is a promis-
ing method for retrieval of oocytes in urgent settings. AIs
with gonadotropin are recommended in patients with estrogen-
sensitive cancers and should be an essential component of a COS
protocol for these patients. In all cases,ovarian reserve and E2 levels
should be assessed prior to initiating COS to avoid adverse effects.
Other methods may emerge as more effective and safer in
preserving fertility in urgent or estrogen-sensitive cases. In vitro
maturation of oocytes is one such proposed method of fertility
preservation that would be advantageous in these settings; how-
ever, at this time, it is still considered an experimental procedure
(18, 61). Similarly, freezing of cortical strips of ovarian tissue is also
a potential option although investigational. To date, few oncology
patients have utilized their cryopreserved embryos and oocytes
post-treatment, thus, data regarding efficacy in this population
are lacking. While pregnancy outcomes in this population are still
unknown overall, a previous study by Noyes et al. shows promis-
ing results (62). Further research and alternative protocols may be
necessary and crucial in providing a greater opportunity for fer-
tility preservation and better comprehensive care of female cancer
patients.
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